Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy

Cancer Lett. 2013 Jul 10;335(1):214-8. doi: 10.1016/j.canlet.2013.02.017. Epub 2013 Feb 16.

Abstract

We investigated whether statin use is associated with reduced risk of recurrence in prostate cancer patients who undergo radiotherapy. A retrospective cohort of 774 patients from a California health plan was followed for 5 years. Statin use prior to, during and after radiotherapy was not associated with prostate cancer recurrence [hazard ratio=0.99 (0.70-1.39), 0.87 (0.62-1.22) and 0.78 (0.55-1.09), respectively] in multivariable Cox models. No clear dose-response relationship was observed for average daily statin dose or duration of statin use. Our findings do not support a preventive benefit of statins in prostate cancer recurrence after radiotherapy.

MeSH terms

  • Aged
  • Cohort Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / drug therapy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Recurrence, Local / chemically induced*
  • Neoplasm Recurrence, Local / prevention & control
  • Proportional Hazards Models
  • Prostatic Neoplasms / chemically induced*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / radiotherapy
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors